BMS-184476 Bristol-Myers Squibb.

Abstract

BMS-184476 is a taxane analog under development by Bristol-Myers Squibb for the potential treatment of solid tumors. By February 2001, it had entered phase II trials and, as of May 2002, phase II studies had been carried out in patients with a number of tumor types, including breast, ovarian and non-small-cell lung cancer.

• Authors: Iwao Ojima, Raphaël Geney
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 4 Issue 6 Pg. 732-6 (Jun 2003) ISSN: 1472-4472 [Print] England
• PMID: 12901233 (Publication Type: Journal Article, Review)

Chemical References

• Drugs, Investigational
• Taxoids
• 7-methylthiomethylpaclitaxel
• Paclitaxel

Topics

• Animals
• Clinical Trials, Phase II as Topic (statistics & numerical data)
• Drugs, Investigational (chemistry, pharmacokinetics, therapeutic use)
• Humans
• Neoplasms (drug therapy, metabolism)
• Paclitaxel (analogs & derivatives, chemistry, pharmacokinetics, therapeutic use)
• Taxoids
• Technology, Pharmaceutical (methods)